Ruben Agrelo - Search Results

Year	Number of Results
2004	2
2005	2
2006	3
2007	2
2009	3
2010	2
2011	1
2012	1
2015	1
2017	1
2024	0

1

Agrelo R, Wutz A. Agrelo R, et al. Semin Cell Dev Biol. 2010 Apr;21(2):194-200. doi: 10.1016/j.semcdb.2009.09.017. Epub 2009 Oct 6. Semin Cell Dev Biol. 2010. PMID: 19815084 Review.

2

Cross-talk between aging and cancer: the epigenetic language.

Fraga MF, Agrelo R, Esteller M. Fraga MF, et al. Among authors: agrelo r. Ann N Y Acad Sci. 2007 Apr;1100:60-74. doi: 10.1196/annals.1395.005. Ann N Y Acad Sci. 2007. PMID: 17460165 Review.

3

Cancer progenitors and epigenetic contexts: an Xisting connection.

Agrelo R, Wutz A. Agrelo R, et al. Epigenetics. 2009 Nov 16;4(8):568-70. doi: 10.4161/epi.4.8.10186. Epub 2009 Nov 27. Epigenetics. 2009. PMID: 19923898 Review.

4

Response: the diversity of proteins linking Xist to gene silencing.

Wutz A, Agrelo R. Wutz A, et al. Among authors: agrelo r. Dev Cell. 2012 Oct 16;23(4):680. doi: 10.1016/j.devcel.2012.09.017. Dev Cell. 2012. PMID: 23079595 Free article. No abstract available.

5

ConteXt of change--X inactivation and disease.

Agrelo R, Wutz A. Agrelo R, et al. EMBO Mol Med. 2010 Jan;2(1):6-15. doi: 10.1002/emmm.200900053. EMBO Mol Med. 2010. PMID: 20043281 Free PMC article.

6

Promoter hypermethylation as a mechanism for Lamin A/C silencing in a subset of neuroblastoma cells.

Rauschert I, Aldunate F, Preussner J, Arocena-Sutz M, Peraza V, Looso M, Benech JC, Agrelo R. Rauschert I, et al. Among authors: agrelo r. PLoS One. 2017 Apr 19;12(4):e0175953. doi: 10.1371/journal.pone.0175953. eCollection 2017. PLoS One. 2017. PMID: 28422997 Free PMC article.

7

SATB1 defines the developmental context for gene silencing by Xist in lymphoma and embryonic cells.

Agrelo R, Souabni A, Novatchkova M, Haslinger C, Leeb M, Komnenovic V, Kishimoto H, Gresh L, Kohwi-Shigematsu T, Kenner L, Wutz A. Agrelo R, et al. Dev Cell. 2009 Apr;16(4):507-16. doi: 10.1016/j.devcel.2009.03.006. Dev Cell. 2009. PMID: 19386260 Free PMC article.

8

A novel Werner Syndrome mutation: pharmacological treatment by read-through of nonsense mutations and epigenetic therapies.

Agrelo R, Sutz MA, Setien F, Aldunate F, Esteller M, Da Costa V, Achenbach R. Agrelo R, et al. Epigenetics. 2015;10(4):329-41. doi: 10.1080/15592294.2015.1027853. Epigenetics. 2015. PMID: 25830902 Free PMC article.

9

Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency.

Castells A, Payá A, Alenda C, Rodríguez-Moranta F, Agrelo R, Andreu M, Piñol V, Castellví-Bel S, Jover R, Llor X, Pons E, Elizalde JI, Bessa X, Alcedo J, Saló J, Medina E, Naranjo A, Esteller M, Piqué JM; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Castells A, et al. Among authors: agrelo r. Clin Cancer Res. 2006 Mar 15;12(6):1686-92. doi: 10.1158/1078-0432.CCR-05-1581. Clin Cancer Res. 2006. PMID: 16551850

10

The impact of MECP2 mutations in the expression patterns of Rett syndrome patients.

Ballestar E, Ropero S, Alaminos M, Armstrong J, Setien F, Agrelo R, Fraga MF, Herranz M, Avila S, Pineda M, Monros E, Esteller M. Ballestar E, et al. Among authors: agrelo r. Hum Genet. 2005 Jan;116(1-2):91-104. doi: 10.1007/s00439-004-1200-0. Epub 2004 Nov 11. Hum Genet. 2005. PMID: 15549394

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

15 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year